The investigators aim to investigate the patient's tumor neoantigen to generate "personalized
cancer vaccine" and then to expand autologous dendritic cells-cytokine-induced killer cells
(DC-CIK). The autologous DC-CIK will be cultured in vitro and re-infused into patients.